PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives

SIMPLE SUMMARY: The development of small agents targeting the B-cell receptor (BCR) pathway revolutionized the treatment of chronic lymphocytic leukemia (CLL). BCR-dependent leukemic cell proliferation is governed by phosphoinositide 3-kinase (PI3K) signaling. The selective PI3Kδ inhibitor idelalisi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hus, Iwona, Puła, Bartosz, Robak, Tadeusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945984/
https://www.ncbi.nlm.nih.gov/pubmed/35326722
http://dx.doi.org/10.3390/cancers14061571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945984/
https://www.ncbi.nlm.nih.gov/pubmed/35326722
http://dx.doi.org/10.3390/cancers14061571

Ejemplares similares